Partnering for Precision in Cancer Care: How Atostek Helped EmpNia Develop FDA-Cleared eMotus™
EmpNia’s newly FDA-cleared eMotus™ system promises to transform respiratory motion tracking in radiation therapy — and Atostek is proud to have contributed as a key software development partner in this groundbreaking project.
When EmpNia set out to revolutionize respiratory motion management in radiation therapy, they had a clear mission: to create a solution that was simple, effective, and accessible across all clinical settings. Now, with FDA clearance for their flagship product eMotus™, that mission is becoming reality — and Atostek is proud to have played a part in making it happen.
A Novel Approach to a Critical Challenge
Respiratory motion is one of the most persistent challenges in delivering precise image-guided radiation therapy. Existing solutions are often difficult to use, disruptive to clinical workflows, and incompatible with many imaging and therapy systems. EmpNia’s answer to these barriers is eMotus: a disposable sensor pad paired with intuitive software for real-time motion tracking — designed for universal compatibility, rapid setup, and cost-effectiveness.
A Key Software Partner
Atostek was selected as one of EmpNia’s core technology partners during the development of eMotus. Atostek’s team focused on delivering high-reliability software that integrates seamlessly with clinical systems and hardware, while ensuring regulatory compliance and real-time performance. Working closely with EmpNia’s expert team across time zones and development stages, the team helped turn a bold concept into a commercially viable and FDA-cleared product.
“eMotus posed a unique and rewarding challenge — combining demanding real-time performance with strict regulatory FDA Class II requirements. We’re proud to have supported EmpNia in building a product that now has the potential to truly improve cancer care.”
— Mika Torhola, Director, New Business, Atostek
A Shared Commitment to Impact
EmpNia’s launch from stealth mode and entry into the U.S. healthcare market marks a significant milestone — not only for their company, but for the future of motion management in radiation therapy.
“Atostek was a vital partner in the development of the eMotus system. Their team brought deep technical knowledge, medical software experience, and a collaborative spirit that helped turn our vision into a cleared, market-ready product. It was a long road — and we travelled it well together.”
— Manojeet Bhattacharya, PhD, Founder & CEO, EmpNia Inc.
Founded in 2020 and headquartered in Minneapolis, Minnesota, EmpNia Inc. develops innovative, practical, and universally accessible medical technologies that solve persistent challenges in radiation therapy and diagnostic imaging. EmpNia’s flagship product, eMotus, is an FDA-cleared disposable sensor pad that provides simple, effective respiratory motion management for precision radiation therapy in any clinical setting. For more information, please visit www.empnia.com.